Connectivity with Iain Duncan

Below are a list of references I have read and used as a basis for reporting Tc-PSMA scans. The first list refers specifically to Tc-PSMA and the second list to GA-PSMA.

Research on Tc-PSMA

  1. Lawal, I. O., Ankrah, A. O., Mokgoro, N. P., Vorster, M., Maes, A., & Sathekge, M. M. (2017). Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT. Prostate, 77(11), 1205–1212. https://doi.org/10.1002/pros.23379
  2. Su, H.-C., Xu, X.-P., Dai, B., Ling, G.-W., Zhu, Y., Hu, S.-L., & Ye, D.-W. (2016). Evaluation of 99m Tc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian Journal of Andrology, 19(3), 267. https://doi.org/10.4103/1008-682x.192638
  3. Schmidkonz, C., Hollweg, C., Beck, M., Reinfelder, J., Goetz, T. I., Sanders, J. C., Schmidt, D., Prante, O., Bäuerle, T., Cavallaro, A., Uder, M., Wullich, B., Goebell, P., Kuwert, T., & Ritt, P. (2018). 99mTc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate, 78(1), 54–63. https://doi.org/10.1002/pros.23444
  4. Langbein, T., Chaussé, G., & Baum, R. P. (2018). Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies. Journal of Nuclear Medicine, 59(8), 1172–1173. https://doi.org/10.2967/jnumed.118.214379
  5. Vallabhajosula, S., Nikolopoulou, A., Babich, J. W., Osborne, J. R., Tagawa, S. T., Lipai, I., Solnes, L., Maresca, K. P., Armor, T., Joyal, J. L., Crummet, R., Stubbs, J. B., & Goldsmith, S. J. (2014). 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 55(11), 1791–1798. https://doi.org/10.2967/jnumed.114.140426
  6. Dér, J., Tenke, P., Joniau, S., Slawin, K., Ellis, W., Alekseev, B., Buzogány, I., Mishugin, S., Klein, E., Stolz, J., Student, V., Matveev, V., Köves, B., Babich, J., Youssoufian, H., Stambler, N., Armor, T., & Israel, R. (2014). C75: A phase 2 study of technetium Tc 99m trofolastat chloride (MIP-1404) SPECT/CT to identify local disease and lymph node metastases in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) for prosta. European Urology Supplements, 13(6), e1263-e1263a. https://doi.org/10.1016/S1569-9056(14)61464-0
  7. Hillier, S. M., Maresca, K. P., Lu, G. L., Merkin, R. D., Marquis, J. C., Zimmerman, C. N., Eckelman, W. C., Joyal, J. L., & Babich, J. W. (2013). Tc-99m-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 54(8), 1369–1376. https://doi.org/DOI 10.2967/jnumed.112.116624
  8. Reinfelder, J., Kuwert, T., Prante, O., Wullich, B., Hennig, P., Beck, M., Sanders, J., Ritt, P., Schmidt, D., & Goebell, P. (2015). First experience with PSMA ­ SPECT / CT using a Tc ­ labeled PSMA inhibitor for patients with biochemical recurrence of prostate cancer. J Nucl Med, 56, Suppl 3 67.
  9. Maurer, T., Weirich, G., Schottelius, M., Weineisen, M., Frisch, B., Okur, A., Kübler, H., Thalgott, M., Navab, N., Schwaiger, M., Wester, H. J., Gschwend, J. E., & Eiber, M. (2015). Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. European Urology, 68(3). https://doi.org/10.1016/j.eururo.2015.04.034
  10. Stanley, J., John, W., Cornell, W., College, M., & York, N. (n.d.). Prostate cancer using PSMA targeted molecular imaging probe , Tc-MIP-1404 : Phase I clinical study in patients undergoing radical prostatectomy SPECT in Patients Prior to Prostatectomy.

Research on Ga-PSMA

  1. Bahler, C. D., Green, M., Hutchins, G. D., Cheng, L., Magers, M. J., Fletcher, J., & Koch, M. O. (2020). Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology. The Journal of Urology, 203(1), 92–99. https://doi.org/10.1097/JU.0000000000000501
  2. Berger, I., Annabattula, C., Lewis, J., Shetty, D. V., Kam, J., MacLean, F., Arianayagam, M., Canagasingham, B., Ferguson, R., Khadra, M., Ko, R., Winter, M., Loh, H., & Varol, C. (2018). 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: Correlation with final histopathology. Prostate Cancer and Prostatic Diseases, 21(2), 204–211. https://doi.org/10.1038/s41391-018-0048-7
  3. Bravaccini, S., Puccetti, M., Bocchini, M., Ravaioli, S., Celli, M., Scarpi, E., De Giorgi, U., Tumedei, M. M., Raulli, G., Cardinale, L., & Paganelli, G. (2018). PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-22594-1
  4. Chiu, L. W., Lawhn-Heath, C., Behr, S., Juarez, R., Perez, P. M., Lobach, I., Bucknor, M. D., Hope, T. A., & Flavell, R. R. (2020). Factors predicting metastatic disease in 68 Ga-PSMA-11 PET positive osseous lesions in prostate cancer. Journal of Nuclear Medicine, jnumed.119.241174. https://doi.org/10.2967/jnumed.119.241174
  5. Donato, P., Roberts, M. J., Morton, A., Kyle, S., Coughlin, G., Esler, R., Dunglison, N., Gardiner, R. A., & Yaxley, J. (2019). Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. European Journal of Nuclear Medicine and Molecular Imaging, 46(1). https://doi.org/10.1007/s00259-018-4160-7
  6. Emmett, L., Tang, R., Nandurkar, R. H., Hruby, G., Roach, P. J., Watts, J. A., Cusick, T., Kneebone, A., Ho, B., Chan, L., Leeuwen, P. van, Scheltema, M., Nguyen, A., Yin, C., Scott, A., Tang, C., McCarthy, M., Fullard, K., Roberts, M., … Stricker, P. (2019). 3-year freedom from progression following 68GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial. Journal of Nuclear Medicine, jnumed.119.235028. https://doi.org/10.2967/jnumed.119.235028
  7. Haupt, F., Dijkstra, L., Alberts, I., Sachpekidis, C., Fech, V., Boxler, S., Gross, T., Holland-Letz, T., Zacho, H. D., Haberkorn, U., Rahbar, K., Rominger, A., & Afshar-Oromieh, A. (2020). 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol. European Journal of Nuclear Medicine and Molecular Imaging, 47(3), 624–631. https://doi.org/10.1007/s00259-019-04548-5
  8. Hofman, M. S., Hicks, R. J., Maurer, T., & Eiber, M. (2018). Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics : A Review Publication of the Radiological Society of North America, Inc, 38(1). https://doi.org/10.1148/rg.2018170108
  9. Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., Wong, L.-M., Taubman, K., Ting Lee, S., Hsiao, E., Roach, P., Nottage, M., Kirkwood, I., Hayne, D., Link, E., … Murphy, D. G. (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)30314-7
  10. Koseoglu, E., Kordan, Y., Kilic, M., Sal, O., Seymen, H., Kiremit, M. C., Armutlu, A., Ertoy Baydar, D., Altinmakas, E., Vural, M., Falay, O., Canda, A. E., Balbay, D., Demirkol, M. O., & Esen, T. (2020). Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4–5 index lesions undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 1–8. https://doi.org/10.1038/s41391-020-00270-8
  11. Kuten, J., Fahoum, I., Savin, Z., Shamni, O., Gitstein, G., Hershkovitz, D., Mabjeesh, N. J., Yossepowitch, O., Mishani, E., & Even-Sapir, E. (2020). Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. Journal of Nuclear Medicine, 61(4), 527–532. https://doi.org/10.2967/JNUMED.119.234187
  12. Lawal, I. O., Ankrah, A. O., Mokgoro, N. P., Vorster, M., Maes, A., & Sathekge, M. M. (2017). Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT. Prostate, 77(11), 1205–1212. https://doi.org/10.1002/pros.23379
  13. Öbek, C., Doğanca, T., Demirci, E., Ocak, M., Kural, A. R., Yıldırım, A., Yücetaş, U., Demirdağ, Ç., Erdoğan, S. M., & Kabasakal, L. (2017). The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 44(11), 1806–1812. https://doi.org/10.1007/s00259-017-3752-y
  14. Ortega C, Schaefferkoetter J, Anconina R, Hawsawy A, Hussey D, Veit-Haibach P, and M. U. (2019). Evaluation of molecular imaging PSMA score (PROMISE) in the context of lesion size: do we need a correction factor? J Nucl Med, 60(supplement 1), 262. http://jnm.snmjournals.org/content/60/supplement_1/262.short?rss=1&related-urls=yes&legid=jnumed%3B60%2Fsupplement_1%2F262&utm_source=TrendMD&utm_medium=cpc&utm_campaign=J_Nucl_Med_TrendMD_0
  15. Ortega, C., Schaefferkoetter, J., Veit-Haibach, P., Anconina, R., Berlin, A., Perlis, N., & Metser, U. (2020). 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria. Journal of Nuclear Medicine, jnumed.120.241737. https://doi.org/10.2967/jnumed.120.241737
  16. Schmidkonz, C., Cordes, M., Goetz, T. I., Prante, O., Kuwert, T., Ritt, P., Uder, M., Wullich, B., Goebell, P., & Bäuerle, T. (2019). 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Annals of Nuclear Medicine, 33(10), 766–775. https://doi.org/10.1007/s12149-019-01387-0
  17. Sonni, I., Eiber, M., Fendler, W. P., Alano, R. M., Vangala, S. S., Kishan, A. U., Nickols, N., Rettig, M. B., Reiter, R., Czernin, J., & Calais, J. (2020). Impact of 68 Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study. Journal of Nuclear Medicine, 61(8), jnumed.119.237602. https://doi.org/10.2967/jnumed.119.237602
  18. Su, H.-C., Xu, X.-P., Dai, B., Ling, G.-W., Zhu, Y., Hu, S.-L., & Ye, D.-W. (2016). Evaluation of 99m Tc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian Journal of Andrology, 19(3), 267. https://doi.org/10.4103/1008-682x.192638
  19. van Leeuwen, P. J., Donswijk, M., Nandurkar, R., Stricker, P., Ho, B., Heijmink, S., Wit, E. M. K., Tillier, C., van Muilenkom, E., Nguyen, Q., van der Poel, H. G., & Emmett, L. (2019). Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cance. BJU International, 124(1), 62–68. https://doi.org/10.1111/bju.14506
  20. Afaq, A., Alahmed, S., Chen, S., Lengana, T., Haroon, A., Payne, H., Ahmed, H., Punwani, S., Sathekge, M., & Bomanji, J. (2017). 68 Ga-PSMA PET/CT impact on prostate cancer management. Journal of Nuclear Medicine, jnumed.117.192625. https://doi.org/10.2967/jnumed.117.192625
  21. Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., Weichert, W., Kopka, K., Debus, J., & Haberkorn, U. (2014). The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 42(2), 197–209. https://doi.org/10.1007/s00259-014-2949-6
  22. Afshar-Oromieh, A., Debus, N., Uhrig, M., Hope, T. A., Evans, M. J., Holland-Letz, T., Giesel, F. L., Kopka, K., Hadaschik, B., Kratochwil, C., & Haberkorn, U. (2018). Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 45(12). https://doi.org/10.1007/s00259-018-4079-z
  23. Afshar-Oromieh, A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Mier, W., Haufe, S., Debus, N., Eder, M., Eisenhut, M., Schäfer, M., Neels, O., Hohenfellner, M., Kopka, K., Kauczor, H. U., Debus, J., & Haberkorn, U. (2017). Diagnostic performance of68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 44(8). https://doi.org/10.1007/s00259-017-3711-7
  24. Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., Kirkham, A. P., Oldroyd, R., Parker, C., & Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822. https://doi.org/10.1016/S0140-6736(16)32401-1
  25. Akdemir, E. N., Tuncel, M., Akyol, F., Bilen, C. Y., Baydar, D. E., Karabulut, E., Ozen, H., & Caglar, M. (2018). 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer. World Journal of Urology, 0123456789. https://doi.org/10.1007/s00345-018-2460-y
  26. Ballas, L. K., de Castro Abreu, A. L., & Quinn, D. I. (2016). What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 57(Supplement_3). https://doi.org/10.2967/jnumed.115.170142
  27. Barbosa, F. G., Queiroz, M. A., Nunes, R. F., Viana, P. C. C., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2019). Revisiting prostate cancer recurrence with PSMA PET: Atlas of typical and atypical patterns of spread. Radiographics, 39(1). https://doi.org/10.1148/rg.2019180079
  28. Bashir, U., Tree, A., Mayer, E., Levine, D., Parker, C., Dearnaley, D., & Oyen, W. J. G. (2019). Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 46(4), 901–907. https://doi.org/10.1007/s00259-018-4249-z
  29. Beck, M., Reinfelder, J., Ritt, P., Sanders, J., & Torsten, K. (2016). Whole ­ Body Scintigraphy and Quantitative SPECT / CT Using the PSMA ­ Agent Tc ­ 99m ­ MIP ­ 1404 in the Preoperative Staging of Prostate Cancer ­ Preliminary Results. 57, 2016.
  30. Beheshti, M., Manafi-Farid, R., Geinitz, H., Vali, R., Loidl, W., Mottaghy, F. M., & Langsteger, W. (2020). Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases. Journal of Nuclear Medicine, jnumed.119.238071. https://doi.org/10.2967/JNUMED.119.238071
  31. Beheshti, M., Manafi-Farid, R., Geinitz, H., Vali, R., Loidl, W., Mottaghy, F. M., & Langsteger, W. (2020). Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases. Journal of Nuclear Medicine, jnumed.119.238071. https://doi.org/10.2967/jnumed.119.238071
  32. Bieth, M., Krönke, M., Tauber, R., Dahlbender, M., Retz, M., Nekolla, S. G., Menze, B., Maurer, T., Eiber, M., & Schwaiger, M. (2017). Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68 Ga-PSMA PET/CT. Journal of Nuclear Medicine, 58(10). https://doi.org/10.2967/jnumed.116.189050
  33. Bluemel, C., Linke, F., Herrmann, K., Simunovic, I., Eiber, M., Kestler, C., Buck, A. K., Schirbel, A., Bley, T. A., Wester, H. J., Vergho, D., & Becker, A. (2016). Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Research, 6(1). https://doi.org/10.1186/s13550-016-0233-4
  34. Bouchelouche, K., Turkbey, B., & Choyke, P. L. (2016). PSMA PET and Radionuclide Therapy in Prostate Cancer. In Seminars in Nuclear Medicine (Vol. 46, Issue 6). https://doi.org/10.1053/j.semnuclmed.2016.07.006
  35. Calais, J., Ceci, F., Eiber, M., Hope, T. A., Hofman, M. S., Rischpler, C., Bach-Gansmo, T., Nanni, C., Savir-Baruch, B., Elashoff, D., Grogan, T., Dahlbom, M., Slavik, R., Gartmann, J., Nguyen, K., Lok, V., Jadvar, H., Kishan, A. U., Rettig, M. B., … Czernin, J. (2019). 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncology, July. https://doi.org/10.1016/s1470-2045(19)30415-2
  36. Calais, J., Czernin, J., Cao, M., Kishan, A. U., Hegde, J. V, Shaverdian, N., Sandler, K. A., Chu, F.-I., King, C. R., Steinberg, M. L., Rausher, I., Schmidt-Hegemann, N.-S., Poeppel, T., Hetkamp, P., Ceci, F., Herrmann, K., Fendler, W. P., Eiber, M., & Nickols, N. G. (2017). (68)Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, jnumed.117.201749. https://doi.org/10.2967/jnumed.117.201749
  37. Calais, J., Kishan, A. U., Cao, M., Fendler, W. P., Eiber, M., Herrmann, K., Ceci, F., Reiter, R. E., Matthew, R. B., Hegde, J. V., Shaverdian, N., King, C. R., Steinberg, M. L., Czernin, J., & Nickols, N. G. (2018). Potential impact of 68 Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. Journal of Nuclear Medicine, jnumed.118.209387. https://doi.org/10.2967/jnumed.118.209387
  38. Calais, J., Kishan, A. U., Cao, M., Fendler, W. P., Eiber, M., Herrmann, K., Ceci, F., Reiter, R. E., Rettig, M. B., Hegde, J. V, Shaverdian, N., King, C. R., Steinberg, M. L., Czernin, J., & Nickols, N. G. (2018). Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(11), 1714–1721. https://doi.org/10.2967/jnumed.118.209387
  39. Ceci, F., Bianchi, L., Borghesi, M., Polverari, G., Farolfi, A., Briganti, A., Schiavina, R., Brunocilla, E., Castellucci, P., & Fanti, S. (2020). Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47(1), 136–146. https://doi.org/10.1007/s00259-019-04505-2
  40. Cho, S. Y. (2018). Proposed Criteria Positions PSMA PET for the Future. Journal of Nuclear Medicine, 1993, jnumed.117.204057. https://doi.org/10.2967/jnumed.117.204057
  41. Corfield, J., Perera, M., Bolton, D., & Lawrentschuk, N. (2018). 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World Journal of Urology, 36(4), 519–527. https://doi.org/10.1007/s00345-018-2182-1
  42. Cremonesi, Marta; Ferrari, Mahila; Bodei, Lisa; Tosi, Giampiero; Paganelli, G. (2006). The Journal of Nuclear Medicine. The Journal of Nuclear Medicine, 47(9), 1467–1475. http://jnm.snmjournals.org/content/56/supplement_3/1279?cited-by=yes&legid=jnumed;56/supplement_3/1279
  43. Dabasi, G., Barra, M., Tenke, P., Joniau, S., Goffin, K., Slawin, K., Ellie, W., Alekseev, B., Buzogany, I., Mishugin, S., Klein, E., Stolz, J., Student, V., Matveev, V., & Armor, T. (2014). Correlation of Technetium Tc99m trofolastat chloride (MIP-1404) uptake using SPECT/CT with histopathology: A phase 2 study of prostate cancer (PCa) patients undergoing radical prostatectomy (RP) with extended lymph node dissection (ePLND). Eur J Nucl Med Mol Imaging, 41(Suppl 2), S236–S237.
  44. Demirci, E., Kabasakal, L., Şahin, O. E., Akgün, E., Gültekin, M. H., Doǧanca, T., Tuna, M. B., Öbek, C., Kiliç, M., Esen, T., & Kural, A. R. (2019). Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nuclear Medicine Communications, 40(1), 86–91. https://doi.org/10.1097/MNM.0000000000000942
  45. Dér, J., Tenke, P., Joniau, S., Slawin, K., Ellis, W., Alekseev, B., Buzogány, I., Mishugin, S., Klein, E., Stolz, J., Student, V., Matveev, V., Köves, B., Babich, J., Youssoufian, H., Stambler, N., Armor, T., & Israel, R. (2014). C75: A phase 2 study of technetium Tc 99m trofolastat chloride (MIP-1404) SPECT/CT to identify local disease and lymph node metastases in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) for prosta. European Urology Supplements, 13(6), e1263-e1263a. https://doi.org/10.1016/S1569-9056(14)61464-0
  46. Eiber, M., Herrmann, K., Calais, J., Hadaschihk, B., Giesel, F. L., Hartenbach, M., Hope, T. A., Reiter, R., Maurer, T., Weber, W. A., & Fendler, W. P. (2017). PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. Journal of Nuclear Medicine, jnumed.117.198119. https://doi.org/10.2967/jnumed.117.198119
  47. Eiber, M., Herrmann, K., Calais, J., Hadaschihk, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., & Fendler, W. P. (2017). PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, jnumed.117.198119. https://doi.org/10.2967/jnumed.117.198119
  48. Emmett, L., Van Leeuwen, P., Nandurkar, R., Scheltema, M. J., Cusick, T., Hruby, G., Kneebone, A., Eade, T., Fogarty, G., Jagavkar, R., Nguyen, Q., Ho, B., Joshua, A. M., & Stricker, P. (2017). Treatment outcomes from 68 GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.196683
  49. Evans, J. D., Jethwa, K. R., Ost, P., Williams, S., Kwon, E. D., Lowe, V. J., & Davis, B. J. (2018). Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 8(1). https://doi.org/10.1016/j.prro.2017.07.011
  50. Fanti, S., Hadaschik, B., & Herrmann, K. (2020). Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 61(5), 678–682. https://doi.org/10.2967/jnumed.119.233817
  51. Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., Hofman, M. S., Eiber, M., Schwarzenbock, S., Castellucci, P., Bellisario, C., Chauvie, S., Bergesio, F., Emmett, L., Haberkorn, U., Virgolini, I., Schwaiger, M., Hicks, R. J., Krause, B. J., & Chiti, A. (2017). Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 44(10). https://doi.org/10.1007/s00259-017-3725-1
  52. Farolfi, A., Ceci, F., Castellucci, P., Graziani, T., Siepe, G., Lambertini, A., Schiavina, R., Lodi, F., Morganti, A. G., & Fanti, S. (2019). 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 46(1), 11–19. https://doi.org/10.1007/s00259-018-4066-4
  53. Fendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., Emmett, L., Zacho, H. D., Ilhan, H., Wetter, A., Rischpler, C., Schoder, H., Burger, I. A., Gartmann, J., Smith, R., … Hope, T. A. (2019). Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncology, 5(6). https://doi.org/10.1001/jamaoncol.2019.0096
  54. Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., Giesel, F., Haberkorn, U., Hope, T. A., Kopka, K., Krause, B. J., Mottaghy, F. M., Schöder, H., Sunderland, J., Wan, S., Wester, H. J., Fanti, S., & Herrmann, K. (2017). 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 44(6). https://doi.org/10.1007/s00259-017-3670-z
  55. Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017). (177)Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(8), 1196–1200. https://doi.org/10.2967/jnumed.117.191023
  56. Gaertner, F. C., Halabi, K., Ahmadzadehfar, H., Kürpig, S., Eppard, E., Kotsikopoulos, C., Liakos, N., Bundschuh, R. A., Strunk, H., & Essler, M. (2017). Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.19049
  57. Gafita, A., Rauscher, I., Retz, M., Knorr, K., Heck, M., Wester, H.-J., D’Alessandria, C., Weber, W. A., Eiber, M., & Tauber, R. (2018). Early experience of rechallenge 177 Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC. Journal of Nuclear Medicine, jnumed.118.215715. https://doi.org/10.2967/jnumed.118.215715
  58. Habl, G., Sauter, K., Schiller, K., Dewes, S., Maurer, T., Eiber, M., & Combs, S. E. (2017). 68Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate, 77(8), 920–927. https://doi.org/10.1002/pros.23347
  59. Haidar, M., Chahinian, R., El-Amine, A., Matar, S., Annan, M., & Shamseddine, A. (2020). Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma. Asia Ocean J Nucl Med Biol, 8(2), 136–140. https://doi.org/10.22038/AOJNMB
  60. Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., & Mottet, N. (2014). EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013. European Urology, 65(1), 124–137. https://doi.org/10.1016/j.eururo.2013.09.046
  61. Herrmann, K., Bluemel, C., Weineisen, M., Schottelius, M., Wester, H.-J., Czernin, J., Eberlein, U., Beykan, S., Lapa, C., Riedmiller, H., Krebs, M., Kropf, S., Schirbel, A., Buck, A. K., & Lassmann, M. (2015). Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 56(6). https://doi.org/10.2967/jnumed.115.156133
  62. Hijazi, S., Meller, B., Leitsmann, C., Strauss, A., Meller, J., Ritter, C. O., Lotz, J., Schildhaus, H. U., Trojan, L., & Sahlmann, C. O. (2015). Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate, 75(16). https://doi.org/10.1002/pros.23091
  63. Hijazi, S., Meller, B., Leitsmann, C., Strauss, A., Meller, J., Ritter, C. O., Lotz, J., Schildhaus, H.-U., Trojan, L., & Sahlmann, C. O. (2015). Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography. The Prostate, 75(16), 1934–1940. https://doi.org/10.1002/pros.23091
  64. Hillier, S. M., Maresca, K. P., Lu, G. L., Merkin, R. D., Marquis, J. C., Zimmerman, C. N., Eckelman, W. C., Joyal, J. L., & Babich, J. W. (2013). Tc-99m-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 54(8), 1369–1376. https://doi.org/DOI 10.2967/jnumed.112.116624
  65. Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Ping Thang, S., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., Eu, P., Jackson, P., Scalzo, M., Williams, S. G., & Sandhu, S. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. The Lancet Oncology, 19(6). https://doi.org/10.1016/S1470-2045(18)30198-0
  66. Hope, T. A., Goodman, J. Z., Allen, I. E., Calais, J., Fendler, W. P., & Carroll, P. R. (2019). Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. Journal of Nuclear Medicine, 60(6), 786–793. https://doi.org/10.2967/jnumed.118.219501
  67. Hope, T. A., Truillet, C., Ehman, E. C., Afshar-Oromieh, A., Aggarwal, R., Ryan, C. J., Carroll, P. R., Small, E. J., & Evans, M. J. (2017). 68 Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 58(1). https://doi.org/10.2967/jnumed.116.181800
  68. Hruby, G., Eade, T., Kneebone, A., Emmett, L., Guo, L., Ho, B., Hsiao, E., Schembri, G., Hunter, J., & Kwong, C. (2016). Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiotherapy and Oncology, 11–14. https://doi.org/10.1016/j.radonc.2016.11.023
  69. Jadvar, H. (2015). PSMA PET in Prostate Cancer. Journal of Nuclear Medicine, 56(8), 1131–1132. https://doi.org/10.2967/jnumed.115.157339
  70. Jadvar, H. (2009). PSMA PET in Prostate Cancer. PET Clinics, 4(2), 155–161. https://doi.org/10.1016/j.cpet.2009.05.002
  71. Kesch, C., Vinsensia, M., Radtke, J. P., Schlemmer, H. P., Heller, M., Ellert, E., Holland-Letz, T., Duensing, S., Grabe, N., Afshar-Oromieh, A., Wieczorek, K., Schäfer, M., Neels, O. C., Cardinale, J., Kratochwil, C., Hohenfellner, M., Kopka, K., Haberkorn, U., Hadaschik, B. A., & Giesel, F. L. (2017). Intraindividual comparison of18F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: A retrospective, proof-of-concept study. Journal of Nuclear Medicine, 58(11), 1805–1810. https://doi.org/10.2967/jnumed.116.189233
  72. Koerber, S. A., Stach, G., Kratochwil, C., Haefner, M. F., Rathke, H., Herfarth, K., Kopka, K., Holland-Letz, T., Choyke, P. L., Will, L., Haberkorn, U., Debus, J., & Giesel, F. L. (2019). Lymph node involvement in treatment-naïve prostate cancer patients – correlation of PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic management. Journal of Nuclear Medicine, jnumed.119.227637. https://doi.org/10.2967/jnumed.119.227637
  73. Koerber, S. A., Utzinger, M. T., Kratochwil, C., Kesch, C., Haefner, M. F., Katayama, S., Mier, W., Iagaru, A. H., Herfarth, K., Haberkorn, U., Debus, J., & Giesel, F. L. (2017). 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(12), 1943–1948. https://doi.org/10.2967/jnumed.117.190314
  74. Koerber, S. A., Utzinger, M. T., Kratochwil, C., Kesch, C., Haefner, M., Katayama, S., Mier, W., Iagaru, A. H., Herfarth, K., Haberkorn, U., Debus, J., & Giesel, F. L. (2017). 68 Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. Journal of Nuclear Medicine, jnumed.117.190314. https://doi.org/10.2967/jnumed.117.190314
  75. Kostyszyn, D., Fechter, T., Bartl, N., Grosu, A. L., Gratzke, C., Sigle, A., Mix, M., Ruf, J., Fassbender, T. F., Kiefer, S., Bettermann, A. S., Nicolay, N. H., Spohn, S., Kramer, M. U., Bronsert, P., Guo, H., Qiu, X., Wang, F., Henkenberens, C., … Zamboglou, C. (2020). Convolutional neural network based deep-learning architecture for intraprostatic tumour contouring on PSMA PET images in patients with primary prostate cancer. Journal of Nuclear Medicine, l, jnumed.120.254623. https://doi.org/10.2967/JNUMED.120.254623
  76. Kranzbühler, B., Müller, J., Becker, A. S., Garcia Schüler, H. I., Muehlematter, U., Fankhauser, C. D., Kedzia, S., Guckenberger, M., Kaufmann, P. A., Eberli, D., & Burger, I. A. (2020). Detection rate and localization of prostate cancer recurrence using 68Ga-PSMA-11 PET/MRI in patients with low PSA values £ 0.5 ng/mL. Journal of Nuclear Medicine, 61(2), 194–201. https://doi.org/10.2967/jnumed.118.225276
  77. Kratochwil, C., Afshar-Oromieh, A., Kopka, K., Haberkorn, U., & Giesel, F. L. (2016). Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. In Seminars in Nuclear Medicine (Vol. 46, Issue 5). https://doi.org/10.1053/j.semnuclmed.2016.04.004
  78. Li, X. I. N., Rowe, S., Leal, J., Lodge, M., Gorin, M., Allaf, M., Ross, A., Pienta, K., & Pomper, M. (2017). Normal Organ Uptake Variability on PSMA ­ Targeted 18F ­ DCFPyL PET / CT. Journal of Nuclear Medicine, 57(Supplement 2), Abstract 519. http://jnm.snmjournals.org/content/57/supplement_2/519.short?cited-by=yes&legid=jnumed;57/supplement_2/519
  79. Lütje, S., Heskamp, S., Cornelissen, A. S., Poeppel, T. D., van den Broek, S. A. M. W., Rosenbaum-Krumme, S., Bockisch, A., Gotthardt, M., Rijpkema, M., & Boerman, O. C. (2015). PSMA ligands for radionuclide imaging and therapy of prostate cancer: Clinical status. Theranostics, 5(12), 1388–1401. https://doi.org/10.7150/thno.13348
  80. Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016). Current use of PSMA–PET in prostate cancer management. Nature Reviews Urology, 13(4), 1–10. https://doi.org/10.1038/nrurol.2016.26
  81. Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016). Current use of PSMA–PET in prostate cancer management. Nature Reviews Urology, 13(4), 1–10. https://doi.org/10.1038/nrurol.2016.26
  82. O’Keefe, D. S., Bacich, D. J., Huang, S. S., & Heston, W. D. (2018). A Perspective on the Evolving story of PSMA Biology and PSMA Based Imaging and Endoradiotherapeutic Strategies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(7), 1007–1013. https://doi.org/10.2967/jnumed.117.203877
  83. Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016). Sensitivity, Specificity, and Predictors of Positive 68Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. In European Urology (Vol. 70, Issue 6). https://doi.org/10.1016/j.eururo.2016.06.021
  84. Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., & Murphy, D. G. (2020). Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-. European Urology, 77(4). https://doi.org/10.1016/j.eururo.2019.01.049
  85. Pomykala, K. L., Czernin, J., Grogan, T. R., Armstrong, W. R., Willliams, J., & Calais, J. (2019). Total-body 68 Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines . Journal of Nuclear Medicine, jnumed.119.230318. https://doi.org/10.2967/jnumed.119.230318
  86. Pyka, T., Okamoto, S., Dahlbender, M., Tauber, R., Retz, M., Heck, M., Tamaki, N., Schwaiger, M., Maurer, T., & Eiber, M. (2016). Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 43(12). https://doi.org/10.1007/s00259-016-3435-0
  87. Rauscher, I., Maurer, T., Beer, A. J., Graner, F.-P., Haller, B., Weirich, G., Doherty, A., Gschwend, J. E., Schwaiger, M., & Eiber, M. (2016). Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of Nuclear Medicine, 57(11). https://doi.org/10.2967/jnumed.116.173492
  88. Rauscher, I., Düwel, C., Haller, B., Rischpler, C., Heck, M. M., Gschwend, J. E., Schwaiger, M., Maurer, T., & Eiber, M. (2018). Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. European Urology, 73(5). https://doi.org/10.1016/j.eururo.2018.01.006
  89. Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016). 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. In Cancer Imaging (Vol. 16, Issue 1). https://doi.org/10.1186/s40644-016-0072-6
  90. Reinfelder, J., Kuwert, T., Prante, O., Wullich, B., Hennig, P., Beck, M., Sanders, J., Ritt, P., Schmidt, D., & Goebell, P. (2015). First experience with PSMA ­ SPECT / CT using a Tc ­ labeled PSMA inhibitor for patients with biochemical recurrence of prostate cancer. J Nucl Med, 56, Suppl 3 67.
  91. Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q., Thompson, B., Cusick, T., McCarthy, M., Tang, C., Ho, B., Stricker, P., & Scott, A. (2017). The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, jnumed.117.197160. https://doi.org/10.2967/jnumed.117.197160
  92. Rowe, S., Pienta, K., Pomper, M. G., & Gorin, M. (2017). Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine, jnumed.117.195255. https://doi.org/10.2967/jnumed.117.195255
  93. Sanli, Y., Kuyumcu, S., Sanli, O., Buyukkaya, F., İribaş, A., Alcin, G., Darendeliler, E., Ozluk, Y., Yildiz, S. O., & Turkmen, C. (2017). Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Annals of Nuclear Medicine, 31(9). https://doi.org/10.1007/s12149-017-1207-y
  94. Schmidkonz, C., Cordes, M., Schmidt, D., Bäuerle, T., Goetz, T. I., Beck, M., Prante, O., Cavallaro, A., Uder, M., Wullich, B., Goebell, P., Kuwert, T., & Ritt, P. (2018). 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1–11. https://doi.org/10.1007/s00259-018-4042-z
  95. Schwarzenböck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., Afshar-Oromieh, A., Herrmann, K., & Eiber, M. (2017). PSMA Ligands for PET-Imaging of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(10), 1545–1552. https://doi.org/10.2967/jnumed.117.191031
  96. Schwenck, J., Rempp, H., Reischl, G., Kruck, S., Stenzl, A., Nikolaou, K., Pfannenberg, C., & la Fougère, C. (2017). Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 44(1). https://doi.org/10.1007/s00259-016-3490-6
  97. Seifert, R., Herrmann, K., Kleesiek, J., Schafers, M. A., Shah, V., Xu, Z., Chabin, G., Garbic, S., Spottiswoode, B., & Rahbar, K. (2020). Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer. Journal of Nuclear Medicine, jnumed.120.242057. https://doi.org/10.2967/jnumed.120.242057
  98. Seifert, R., Herrmann, K., Kleesiek, J., Schafers, M. A., Shah, V., Xu, Z., Chabin, G., Garbic, S., Spottiswoode, B., & Rahbar, K. (2020). Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer. Journal of Nuclear Medicine, jnumed.120.242057. https://doi.org/10.2967/jnumed.120.242057
  99. Slawin, K. M., Ellis, W. J., Tenke, P., Joniau, S., Alekseev, B. Y., Buzogány, I., Mishugin, S., Klein, E. A., Karnes, R. J., Scherr, D., Yuh, B. E., Jarrard, D. F., Trabulsi, E. J., Stolz, J., Babich, J., Youssoufian, H., Stambler, N., Armor, T., & Israel, R. J. (2014). A phase II study of 99m Tc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An int. Journal of Clinical Oncology, 32(4_suppl), 94–94. https://doi.org/10.1200/jco.2014.32.4_suppl.94
  100. Society of Nuclear Medicine (1953- ), X., Rowe, S., Leal, J., Lodge, M., Gorin, M., Allaf, M., Ross, A., Pienta, K., & Pomper, M. (2016). The Journal of nuclear medicine : JNM. In Journal of Nuclear Medicine (Vol. 57, Issue supplement 2). Society of Nuclear Medicine. http://jnm.snmjournals.org/content/57/supplement_2/519.short?cited-by=yes&legid=jnumed;57/supplement_2/519
  101. Sprute, K., Kramer, V., Koerber, S., Meneses, M., Fernandez, R., Soza-Ried, C., Eiber, M., Weber, W., Rauscher, I., Rahbar, K., Schaefers, M., Watabe, T., Uemura, M., Naka, S., Nonomura, N., Hatazawa, J., Schwab, C., Schütz, V., Hohenfellner, M., … Giesel, F. L. (2020). Diagnostic accuracy of 18 F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. Journal of Nuclear Medicine, jnumed.120.246363. https://doi.org/10.2967/jnumed.120.246363
  102. Stanley, J., John, W., Cornell, W., College, M., & York, N. (n.d.). Prostate cancer using PSMA targeted molecular imaging probe , Tc-MIP-1404 : Phase I clinical study in patients undergoing radical prostatectomy SPECT in Patients Prior to Prostatectomy. 1404.
  103. Stephan, C., Stroebel, G., Heinau, M., Lenz, A., Roemer, A., Lein, M., Schnorr, D., Loening, S. A., & Jung, K. (2005). The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer, 104(5), 993–1003. https://doi.org/10.1002/cncr.21267
  104. Toriihara, A., Nobashi, T., Baratto, L., Duan, H., Moradi, F., Park, S., Hatami, N., Aparici, C., Davidzon, G., & Iagaru, A. (2019). Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, jnumed.119.232504. https://doi.org/10.2967/jnumed.119.232504
  105. Uprimny, C., Kroiss, A. S., Decristoforo, C., Fritz, J., von Guggenberg, E., Kendler, D., Scarpa, L., di Santo, G., Roig, L. G., Maffey-Steffan, J., Horninger, W., & Virgolini, I. J. (2017). 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. European Journal of Nuclear Medicine and Molecular Imaging, 44(6), 941–949. https://doi.org/10.1007/s00259-017-3631-6
  106. Vallabhajosula, S., Polack, B., Jhanwar, Y. S., Nikolopoulou, A., Armor, T., Tagawa, S. T., Scherr, D., Robinson, B., Goldsmith, S. J., & Babich, J. W. (2014). Psma spect imaging with 99mTC-MIP-1404 in patients with prostate cancer (PCA): Comparison with bone scan, Ct or MRI. European Journal of Nuclear Medicine and Molecular Imaging, 41, S236. https://doi.org/10.1007/s00259-014-2901-9
  107. Vallabhajosula, S., Nikolopoulou, A., Babich, J. W., Osborne, J. R., Tagawa, S. T., Lipai, I., Solnes, L., Maresca, K. P., Armor, T., Joyal, J. L., Crummet, R., Stubbs, J. B., & Goldsmith, S. J. (2014). 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 55(11), 1791–1798. https://doi.org/10.2967/jnumed.114.140426
  108. Vallabhajosula, S., Nikolopoulou, A., Babich, J. W., Osborne, J. R., Tagawa, S. T., Lipai, I., Solnes, L., Maresca, K. P., Armor, T., Joyal, J. L., Crummet, R., Stubbs, J. B., & Goldsmith, S. J. (2014). 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 55(11), 1791–1798. https://doi.org/10.2967/jnumed.114.140426
  109. Vallabhajosula, S., Osborne, J., Nikolopoulou, A., Lipai, I., Tagawa, S., Scherr, D., Joyal, J., Armor, T., Goldsmith, S., & Babich, J. (2014). PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer ( PCa ): Phase I studies with Tc ­ MIP ­ 1404. 54(May 2013), 2014.
  110. Van Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., Nguyen, Q., Ho, B., & Emmett, L. (2016). 68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU International, 117(5), 732–739. https://doi.org/10.1111/bju.13397
  111. Virgolini, I., Decristoforo, C., Haug, A., Fanti, S., & Uprimny, C. (2018). Current status of theranostics in prostate cancer. In European Journal of Nuclear Medicine and Molecular Imaging (Vol. 45, Issue 3). https://doi.org/10.1007/s00259-017-3882-2
  112. Vogel, M. M. E., Kroeze, S. G. C., Henkenberens, C., Kirste, S., Becker, J., Burger, I. A., & Derlin, T. (2020). Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [ 68 Ga ] PSMA-PET-guided metastasis-directed therapy. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-04760-8
  113. von Eyben, F. E., Picchio, M., von Eyben, R., Rhee, H., & Bauman, G. (2016). 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus. https://doi.org/10.1016/j.euf.2016.11.002
  114. Wang, B. J., Gao, J., Zhang, Q., Fu, Y., Liu, G., Shi, J., Li, D., Wang, F., & Guo, H. (2020). Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study. In Journal of nuclear medicine : official publication, Society of Nuclear Medicine (Vol. 61, Issue 6). https://doi.org/10.2967/jnumed.119.236059
  115. Woythal, N., Arsenic, R., Kempkensteffen, C., Miller, K., Janssen, J.-C., Huang, K., Makowski, M. R., Brenner, W., & Prasad, V. (2017). Immunohistochemical validation of PSMA-expression measured by 68 Ga-PSMA PET/CT in primary prostate cancer. Journal of Nuclear Medicine, 59(2), jnumed.117.195172. https://doi.org/10.2967/jnumed.117.195172
  116. Zacho, H. D., Nielsen, J. B., Haberkorn, U., Stenholt, L., & Petersen, L. J. (2018). 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. In Clinical Physiology and Functional Imaging (Vol. 38, Issue 6). https://doi.org/10.1111/cpf.12480
  117. Zamboglou, C., Schiller, F., Fechter, T., Wieser, G., Jilg, C. A., Chirindel, A., Salman, N., Drendel, V., Werner, M., Mix, M., Meyer, P. T., & Grosu, A. L. (2016). 68Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer: A voxel-wise comparison. Theranostics, 6(10), 1619–1628. https://doi.org/10.7150/thno.15344
Scan showing spread to a left pelvic lymph node
Scan showing spread to a left pelvic lymph node